783 related articles for article (PubMed ID: 29097600)
1. PD-L1.
Kythreotou A; Siddique A; Mauri FA; Bower M; Pinato DJ
J Clin Pathol; 2018 Mar; 71(3):189-194. PubMed ID: 29097600
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 in cardiovascular disease.
Sun Y; Li L; Wu Y; Yang K
Clin Chim Acta; 2020 Jun; 505():26-30. PubMed ID: 32084380
[TBL] [Abstract][Full Text] [Related]
3. The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint.
Wang Q; Lin W; Tang X; Li S; Guo L; Lin Y; Kwok HF
Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29186904
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
5. What does PD-L1 positive or negative mean?
Ribas A; Hu-Lieskovan S
J Exp Med; 2016 Dec; 213(13):2835-2840. PubMed ID: 27903604
[TBL] [Abstract][Full Text] [Related]
6. Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Shen X; Zhang L; Li J; Li Y; Wang Y; Xu ZX
Front Immunol; 2019; 10():1337. PubMed ID: 31258527
[TBL] [Abstract][Full Text] [Related]
7. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
13. The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Kula A; Dawidowicz M; Kiczmer P; Prawdzic Seńkowska A; Świętochowska E
Exp Mol Pathol; 2020 Oct; 116():104494. PubMed ID: 32679050
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
16. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
17. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
18. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Lau J; Cheung J; Navarro A; Lianoglou S; Haley B; Totpal K; Sanders L; Koeppen H; Caplazi P; McBride J; Chiu H; Hong R; Grogan J; Javinal V; Yauch R; Irving B; Belvin M; Mellman I; Kim JM; Schmidt M
Nat Commun; 2017 Feb; 8():14572. PubMed ID: 28220772
[TBL] [Abstract][Full Text] [Related]
19. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
Luo M; Fu L
Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Liu D; Wang S; Bindeman W
J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
